AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30324553 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with Tenofovir Disoproxil Fumarate (TDF)
Number of subjects: 0
Study 29378991 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tramadol 100 mg (Group BT)
Number of subjects: 120
Study 29378991 — intervention group
Group type: COMPARATOR
Intervention: IV dexamethasone 8 mg (Group BD)
Number of subjects: 120
Study 25230888 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive protocol (two 15-minute walks on the day of surgery)
Number of subjects: 66
Study 25230888 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (one 15-minute walk on the day of surgery)
Number of subjects: 66
Study 25230888 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive protocol
Number of subjects: 66
Study 25230888 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol
Number of subjects: 66
Study 22999636 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster ophthalmicus (HZO) eyes
Number of subjects: 27
Study 22999636 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral clinically unaffected eyes
Number of subjects: 27
Study 22999636 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal sensation
Number of subjects: 27
Study 22999636 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 27
Study 21227563 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 min of monthly practice on a voice advisory manikin
Number of subjects: 606
Study 21227563 — intervention group
Group type: COMPARATOR
Intervention: Control group (no practice)
Number of subjects: 606
Study 18497677 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose rATG (6 mg/kg)
Number of subjects: 160
Study 18497677 — intervention group
Group type: COMPARATOR
Intervention: Divided doses rATG (1.5 mg/kg every other day for 4 days)
Number of subjects: 160
Study 16644795 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PEMI of the upper and lower limbs
Number of subjects: 8
Study 16644795 — intervention group
Group type: COMPARATOR
Intervention: PEMI of the upper limb alone
Number of subjects: 8
Study 16644795 — intervention group
Group type: EXPERIMENTAL
Intervention: PEMI of the lower limb (after release)
Number of subjects: 8
Study 14646646 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral saline wound irrigation
Number of subjects: 30
Study 14646646 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI > 26.3
Number of subjects: 30
Study 14646646 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI < 26.3
Number of subjects: 30
Study 10960528 — intervention group
Group type: EXPERIMENTAL
Intervention: AS-24 (hypotonic storage solution)
Number of subjects: 24
Study 10960528 — intervention group
Group type: COMPARATOR
Intervention: AS-3 (control storage solution)
Number of subjects: 24
Study 8977678 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using a portable desktop lamp with 300 W xenon short arc discharge source and topical 5-aminolaevulinic acid (5-ALA) applied 4 hours before irradiation, 125 J/cm2 at a fluence rate of 70 mW/cm2.
Number of subjects: 40
Study 8977678 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy with liquid nitrogen.
Number of subjects: 40
Study 1309410 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 2% ophthalmic solution, administered twice daily
Number of subjects: 140
Study 1309410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 6371890 — intervention group
Group type: COMPARATOR
Intervention: Metrizamide
Number of subjects: 350
Study 6371890 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 350
Study 30470690 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI-ramucirumab (ram)
Number of subjects: 29
Study 30179056 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent cisplatin (40 mg m‐2) with bowel sparing IMRT (50 Gy/25#/5 wks)
Number of subjects: 75
Study 30179056 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel sparing IMRT
Number of subjects: 75
Study 30179056 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole pelvis + lumbar freehand V30 >55% & V40>35%, whole pelvis WB and FH V40 > 35%, lower pelvis WB and FH V40 >20%
Number of subjects: 75
Study 30179056 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow dose volume constraints
Number of subjects: 75
Study 26531052 — intervention group
Group type: EXPERIMENTAL
Intervention: Mydrane (200 μL of a combination of tropicamide 0.02%, phenylephrine 0.31% and lidocaine 1%)
Number of subjects: 555
Study 26531052 — intervention group
Group type: COMPARATOR
Intervention: Topical regimen (one drop each of tropicamide 0.5% and phenylephrine 10% repeated three times)
Number of subjects: 555
Study 26531052 — intervention group
Group type: EXPERIMENTAL
Intervention: Mydrane
Number of subjects: 555
Study 26531052 — intervention group
Group type: COMPARATOR
Intervention: Topical regimen
Number of subjects: 555
Study 24781517 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg nicotine oral soluble film
Number of subjects: 322
Study 24781517 — intervention group
Group type: COMPARATOR
Intervention: 2 mg nicotine lozenge
Number of subjects: 322
Study 22842780 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptive rehabilitation (PG)
Number of subjects: 30
Study 22842780 — intervention group
Group type: COMPARATOR
Intervention: Back school programme (BG)
Number of subjects: 30
Study 19535699 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium inhalation at an end-tidal concentration of 50 vol% during ischemia-reperfusion
Number of subjects: 8
Study 19535699 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium inhalation at an end-tidal concentration of 50 vol%
Number of subjects: 8
Study 19535699 — intervention group
Group type: COMPARATOR
Intervention: Control (absence of helium inhalation)
Number of subjects: 8
Study 17659458 — intervention group
Group type: COMPARATOR
Intervention: Ligasure technique (LT)
Number of subjects: 86
Study 17659458 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure for prolapse and hemorrhoids (PPH)
Number of subjects: 86
Study 14745327 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction abdominal drainage (drainage group, n = 52)
Number of subjects: 104
Study 14745327 — intervention group
Group type: COMPARATOR
Intervention: No drainage (nondrainage group, n = 52)
Number of subjects: 104
Study 11763721 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 20
Study 11763721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8994935 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain injury (female cases)
Number of subjects: 99
Study 8994935 — intervention group
Group type: COMPARATOR
Intervention: Injured controls (hospitalized for injuries other than CNS)
Number of subjects: 99
Study 8994935 — intervention group
Group type: COMPARATOR
Intervention: Uninjured academic controls
Number of subjects: 99
Study 9435773 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-epileptic medication added to existing drug regime
Number of subjects: 10
Study 9435773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3090314 — intervention group
Group type: EXPERIMENTAL
Intervention: mesna
Number of subjects: 13
Study 3090314 — intervention group
Group type: COMPARATOR
Intervention: ifosfamide alone
Number of subjects: 13
Study 31439831 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg oral cannabidiol
Number of subjects: 33
Study 31439831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 29263660 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting β‐2 agonist (LABA)
Number of subjects: 65
Study 29263660 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting muscarinic antagonist (LAMA)
Number of subjects: 65
Study 29263660 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical traits only for LABA
Number of subjects: 65
Study 29263660 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical traits only for LAMA
Number of subjects: 65
Study 26388284 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium PD solution (125 mmol/L sodium; 1.5%, 2.3%, or 4.25% glucose; osmolarity 338-491 mOsm/L)
Number of subjects: 108
Study 26388284 — intervention group
Group type: COMPARATOR
Intervention: Standard-sodium PD solution (134 mmol/L sodium; 1.5%, 2.3%, or 4.25% glucose; osmolarity 356-509 mOsm/L)
Number of subjects: 108
Study 24614142 — intervention group
Group type: EXPERIMENTAL
Intervention: GUM with scGOS/lcFOS/LCPUFAs (active group)
Number of subjects: 767
Study 24614142 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk group
Number of subjects: 767
Study 24614142 — intervention group
Group type: COMPARATOR
Intervention: GUM without scGOS/lcFOS/LCPUFAs (control group)
Number of subjects: 767
Study 21719695 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone supplementation with testosterone buccal adhesive patches 2 × 30 mg/d for 8 months
Number of subjects: 106
Study 21719695 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraplaque verapamil injections associated with testosterone administration
Number of subjects: 106
Study 21719695 — intervention group
Group type: COMPARATOR
Intervention: Intraplaque verapamil injections associated with a placebo
Number of subjects: 106
Study 21719695 — intervention group
Group type: EXPERIMENTAL
Intervention: PD patients with low bT/fT
Number of subjects: 106
Study 21719695 — intervention group
Group type: COMPARATOR
Intervention: PD patients with normal bT/fT
Number of subjects: 106
Study 21719695 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain and penile deformity examination
Number of subjects: 106
Study 20178254 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a for 48 weeks
Number of subjects: 19
Study 20178254 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa‐2a for 24 weeks
Number of subjects: 19
Study 17223914 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 17223914 — intervention group
Group type: COMPARATOR
Intervention: Cytomegalovirus-specific T-cell immunity
Number of subjects: 0
Study 15237762 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma education video game intervention
Number of subjects: 119
Study 15237762 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 119
Study 11978676 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes prevalence in men
Number of subjects: 11247
Study 11978676 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes prevalence in women
Number of subjects: 11247
Study 11978676 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) prevalence in men
Number of subjects: 11247
Study 11978676 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) prevalence in women
Number of subjects: 11247
Study 11978676 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal glucose tolerance prevalence in the youngest age group (25-34 years)
Number of subjects: 11247
Study 11978676 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall diabetes prevalence in Australia
Number of subjects: 11247
Study 11978676 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of IGT or IFG in Australia
Number of subjects: 11247
Study 10349044 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment with akathisia (n = 15)
Number of subjects: 33
Study 10349044 — intervention group
Group type: COMPARATOR
Intervention: Clozapine treatment without akathisia (n = 18)
Number of subjects: 33
Study 10349044 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment (both groups)
Number of subjects: 33
Study 7493423 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (5 mg) with hypoxic mixture (FiO2 = 12%)
Number of subjects: 8
Study 7493423 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (5 mg) with normoxic mixture
Number of subjects: 8
Study 7493423 — intervention group
Group type: COMPARATOR
Intervention: Hypoxic mixture (FiO2 = 12%)
Number of subjects: 8
Study 7493423 — intervention group
Group type: COMPARATOR
Intervention: Placebo with hypoxic mixture (FiO2 = 12%)
Number of subjects: 8
Study 7493423 — intervention group
Group type: COMPARATOR
Intervention: Placebo with normoxic mixture
Number of subjects: 8
Study 1674394 — intervention group
Group type: EXPERIMENTAL
Intervention: Epanolol 100 mg
Number of subjects: 12
Study 1674394 — intervention group
Group type: EXPERIMENTAL
Intervention: Epanolol 200 mg
Number of subjects: 12
Study 1674394 — intervention group
Group type: EXPERIMENTAL
Intervention: Epanolol 300 mg
Number of subjects: 12
Study 1674394 — intervention group
Group type: EXPERIMENTAL
Intervention: Epanolol (pooled data of 3 doses)
Number of subjects: 12
Study 1674394 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study 6765503 — intervention group
Group type: EXPERIMENTAL
Intervention: Large doses of vitamin B6 and magnesium
Number of subjects: 44
Study 29985978 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin-based mass drug administration (MDA)
Number of subjects: 6
Study 29985978 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin-based MDA co-administered with azithromycin
Number of subjects: 6
Study 29985978 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment arm (azithromycin with ivermectin)
Number of subjects: 6
Study 28743787 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Eluting Balloon (PEB)
Number of subjects: 70
Study 28743787 — intervention group
Group type: COMPARATOR
Intervention: Conventional Balloon Angioplasty (BA)
Number of subjects: 70
Study 26375542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary interlocking nail
Number of subjects: 60
Study 26375542 — intervention group
Group type: COMPARATOR
Intervention: Locking compression plate
Number of subjects: 60
Study 23588058 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Advisory Mannequin (VAM)
Number of subjects: 43
Study 23588058 — intervention group
Group type: COMPARATOR
Intervention: Instructor guidance
Number of subjects: 43
Study 20224451 — intervention group
Group type: EXPERIMENTAL
Intervention: CBEX drink (containing total 2 g of carnosine and anserine)
Number of subjects: 22
Study 20224451 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 22
Study 19723943 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 percent carbamide peroxide (CP10)
Number of subjects: 92
Study 19723943 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 percent carbamide peroxide (CP16)
Number of subjects: 92
Study 17678667 — intervention group
Group type: EXPERIMENTAL
Intervention: Bursts of AC electric stimulation at frequencies of 1 and 4kHz with burst durations ranging from 250 micros to 20 ms
Number of subjects: 26
Study 15247338 — intervention group
Group type: EXPERIMENTAL
Intervention: nevirapine-nevirapine regimen
Number of subjects: 1844
Study 15247338 — intervention group
Group type: COMPARATOR
Intervention: placebo-placebo regimen
Number of subjects: 1844
Study 15247338 — intervention group
Group type: COMPARATOR
Intervention: nevirapine-placebo regimen
Number of subjects: 1844
Study 11109970 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (hCG)
Number of subjects: 310
Study 11109970 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized transvaginal progesterone
Number of subjects: 310
Study 8815984 — intervention group
Group type: EXPERIMENTAL
Intervention: Choerospondias axillaris extract
Number of subjects: 39
Study 8815984 — intervention group
Group type: COMPARATOR
Intervention: Saline gauze
Number of subjects: 39
Study 1564022 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg dose of methylphenidate
Number of subjects: 0
Study 1564022 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated normal controls
Number of subjects: 0
Study 2951114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin treatment
Number of subjects: 0
Study 3027193 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleic acid dot hybridization assay
Number of subjects: 94
Study 3027193 — intervention group
Group type: COMPARATOR
Intervention: Lymphocyte transformation assay
Number of subjects: 94
Study 29575406 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-high compression socks (CS)
Number of subjects: 10
Study 29575406 — intervention group
Group type: COMPARATOR
Intervention: Control (no CS)
Number of subjects: 10
Study 27704195 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhomboid flap repair after fistulectomy
Number of subjects: 40
Study 27704195 — intervention group
Group type: COMPARATOR
Intervention: Z plasty repair after fistulectomy
Number of subjects: 40
Study 24712501 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude visit
Number of subjects: 163
Study 24712501 — intervention group
Group type: EXPERIMENTAL
Intervention: Three good things
Number of subjects: 163
Study 24712501 — intervention group
Group type: EXPERIMENTAL
Intervention: Three funny things
Number of subjects: 163
Study 24712501 — intervention group
Group type: EXPERIMENTAL
Intervention: Using signature strengths in a new way
Number of subjects: 163
Study 24712501 — intervention group
Group type: COMPARATOR
Intervention: Placebo control exercise (early memories)
Number of subjects: 163
Study 22864398 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight (10-30% reduction or increase)
Number of subjects: 40
Study 22864398 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight (own body weight)
Number of subjects: 40
Study 22864398 — intervention group
Group type: EXPERIMENTAL
Intervention: Group × load interaction
Number of subjects: 40
Study 20826878 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring of non-invasive ventilation (NIV) with a modem device (G2)
Number of subjects: 40
Study 20826878 — intervention group
Group type: COMPARATOR
Intervention: Control group (G1)
Number of subjects: 40
Study 17964642 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) applied to the left prefrontal cortex
Number of subjects: 0
Study 17964642 — intervention group
Group type: COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS) applied to the right prefrontal cortex
Number of subjects: 0
Study 16872795 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) intervention
Number of subjects: 67
Study 16872795 — intervention group
Group type: COMPARATOR
Intervention: Information group
Number of subjects: 67
Study 16872795 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 67
Study 16872795 — intervention group
Group type: EXPERIMENTAL
Intervention: SDM group
Number of subjects: 67
Study 15526500 — intervention group
Group type: EXPERIMENTAL
Intervention: Mix 25 (insulin lispro low mixture)
Number of subjects: 175
Study 15526500 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 175
Study 10933350 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 84
Study 10933350 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (7 g twice daily)
Number of subjects: 84
Study 8725472 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (2 mg oral dose)
Number of subjects: 9
Study 8725472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8725472 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 9
Study 1407479 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 8
Study 1407479 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 8
Study 1407479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 4042547 — intervention group
Group type: EXPERIMENTAL
Intervention: Older subjects (63-70 years)
Number of subjects: 9
Study 4042547 — intervention group
Group type: COMPARATOR
Intervention: Young adults
Number of subjects: 9
Study 30765809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 0.15 mg/kg
Number of subjects: 100
Study 30765809 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 100
Study 30007343 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-like dietary pattern with vitamin D3 (10 µg/d) supplements
Number of subjects: 1294
Study 30007343 — intervention group
Group type: COMPARATOR
Intervention: Control group (leaflets on healthy eating)
Number of subjects: 1294
Study 26642244 — intervention group
Group type: EXPERIMENTAL
Intervention: Infinity brush
Number of subjects: 60
Study 26642244 — intervention group
Group type: COMPARATOR
Intervention: Regularly used brush
Number of subjects: 60
Study 23955516 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidified high-flow nasal cannulae (HHHFNC)
Number of subjects: 0
Study 23955516 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 0
Study 23955516 — intervention group
Group type: COMPARATOR
Intervention: NCPAP with Sticky Whiskers®
Number of subjects: 0
Study 23955516 — intervention group
Group type: COMPARATOR
Intervention: NCPAP with Cannualaide®
Number of subjects: 0
Study 22898365 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 5mg
Number of subjects: 301
Study 22898365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 20231568 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 7818
Study 20231568 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 7818
Study 18602144 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (low-fat, plant-based diet, exercise, stress management, group support)
Number of subjects: 93
Study 18602144 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 93
Study 18602144 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated experimental patients
Number of subjects: 93
Study 18602144 — intervention group
Group type: COMPARATOR
Intervention: Untreated control patients
Number of subjects: 93
Study 17067119 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed with cisplatin
Number of subjects: 0
Study 17067119 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 12730476 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced protein energy supplementation
Number of subjects: 0